![](https://bloximages.newyork1.vip.townnews.com/avpress.com/content/tncms/assets/v3/editorial/4/66/466e6432-9d28-5577-93a4-47afa8dc501c/66a36e2eb13ef.image.jpg?crop=592%2C592%2C0%2C104&resize=200%2C200&order=crop%2Cresize)
U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials. At baseline, the average patient had only 13% scalp hair coverage. At week 24, one-third of those patients experienced 80% scalp hair coverage. MUMBAI, India and …